Amgen scoops up Dezima for $300mm plus potential earn-outs of $1.25bn
Concurrent with signing a potential $1.75bn monoclonal antibody development deal with Xencor, Amgen Inc. is acquiring cardiovascular-focused start-up Dezima Pharma BV for $300mm in cash up front, up to $1.25bn in earn-outs based on development and sales achievements, and low single-digit royalties.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com